Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

13 results
Display

Retraction: A Case of Rapid Progression of Hepatocellular Carcinoma after Radiofrequency Ablation

Lee K, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW

To preserve scientific integrity, Journal of Liver Cancer agreed with the authors that this paper be retracted.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of the Outcome after Transarterial Chemoembolization; Refinement of Barcelona Clinic Liver Cancer Stage-B from Eastern Point of View

Izumi N

Transarterial chemoembolization (TACE) is recommended as the first line treatment option for the patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC), however, treatment strategy and evaluation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma

Song DS, Bae SH

Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory efficacy, adverse effects, and high cost, the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Subclassification of Hepatocellular Carcinoma with Barcelona Clinic Liver Cancer Intermediate Stage

Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer (BCLC) intermediate stage includes a highly heterogeneous population. Here, we aimed to sub-classify hepatocellular carcinoma with BCLC intermediate stage for better...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Complete Remission in Patient with Extrahepatic Metastasis after Curative Resection of Hepatocellular Carcinoma by Radiotherapy, Lung Resection and Systemic Chemotherapy

Kim YJ, Lee HW, Lee JH, Sung JS, Kim DY

Surgical resection is mainstay treatment of hepatocellular carcinoma (HCC). However, its prognosis is poor, because of the high incidence of HCC recurrence (cumulative 5-year HCC recurrence rate of 70-80%). The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Complete Response of Single Nodular Large Hepatocellular Carcinoma with Pulmonary Metastasis by Sequential Transarterial Chemoembolization and Sorafenib: A Case Report

Kim GH, Yu HM, Lim CJ, Cho SB

Current guidelines recommend sorafenib as the first-line molecular target agent for advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis and unresectable HCC. Sorafenib was reported to show survival benefit for patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long Term Survival in Patient with Hepatocellular Carcinoma after Surgical Resection of Brain Metastasis: A Case Report

Lee JH, Yu HM, Cho SB

Brain metastasis is a rare condition of extraheptaic metastases in hepatocellular carcinoma (HCC). Patients with hepatocellular carcinoma and brain metastasis have rapidly worsened neurologic signs and symptoms, therefore it is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Experience and Expectation for Molecular Target Therapy in Hepatocellular Carcinoma

Kim DY

Sorafenib, the first-approved molecular targeted agent (MTA), is actively used in patients with advanced hepatocellular carcinoma (HCC) worldwide. Accumulating experiences suggest that the efficacy of this drug is modest and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib

Kim DH, Min GH, Lee DW, Ahn KR, Kim JH, Suh SJ, Jung YK, Yim HJ

Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Complete Response by Multidisciplinary Management in a Patient with Solitary Bone Metastasis after Curative Resection of Hepatocellular Carcinoma

Hwang S, Yang H, Lee HL, Jang JW, Bae SH, Choi JY, Yoon SK

Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the prognosis of patients with extrahepatic metastasis from HCC still remains dismal. The current study presents a case of HCC...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Confirmation of HIF-1α Independent Pathway in the Progression of HepG2 Cells by Hypoxic Condition

Lee SW, Chong JU, Min SO, Kim KS

BACKGROUND/AIMS: When hepatocellular carcinoma (HCC) is exposed to hypoxic condition, HIF-1α is activated and results in angiogenesis and increased tumor burden. Although inhibition of HIF-1α may reduce tumor growth, there...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Rapid Progressive Extrahepatic Metastasis of Hepatocellular Carcinoma after Surgical Resection for Huge Single Mass

Jang ES, Kim H, Choi YR, Cho JY, Yoon YS, Han HS, Kim JH, Kim JW, Jeong SH

Hepatocellular carcinoma (HCC) shows a poor prognosis with high recurrence rate even after surgical resection. To improve prognosis of HCC patient, regular surveillance for high-risk group is recommended, but cost-benefit...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survival Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients Treated with Sorafenib

Kim JH, Yu HM, Hwang Y, Ko SY, Choe WH, Kwon SY

BACKGROUND/AIMS: Nucleos(t)ide analogues (NAs) help reduce the recurrence rate after the curative treatment of hepatitis B related hepatocellular carcinoma (HCC). Sorafenib has been shown to improve survival of advanced HCC...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr